Mark Stenhouse
Direttore/Membro del Consiglio presso PHATHOM PHARMACEUTICALS, INC.
Patrimonio netto: 183 690 $ in data 31/05/2024
Profilo
Mark Stenhouse is an Independent Director at Phathom Pharmaceuticals, Inc. He previously worked as a Director at Prometheus Laboratories, Inc. from 2018 to 2020.
Mark also served as the Vice President-US Immunology at Abbott Laboratories from 2006 to 2010 and as the General Manager-Screening at EXACT Sciences Corp.
from 2019 to 2021.
Prior to that, he held the position of Vice President-U.S.
Immunology at AbbVie, Inc. from 2016 to 2018.
Mark's current job includes being the Chief Operating Officer at Prometheus Biosciences, Inc. from 2021 to 2023.
He completed his undergraduate degree at the College of Charleston.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 23/05/2024 | 19 500 ( 0.03% ) | 183 690 $ | 31/05/2024 |
Posizioni attive di Mark Stenhouse
| Società | Posizione | Inizio |
|---|---|---|
| PHATHOM PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 17/03/2020 |
Precedenti posizioni note di Mark Stenhouse
| Società | Posizione | Fine |
|---|---|---|
| PROMETHEUS BIOSCIENCES, INC. | Direttore operativo | 16/06/2023 |
| EXACT SCIENCES CORPORATION | Corporate Officer/Principal | 01/01/2021 |
Prometheus Laboratories, Inc.
 Prometheus Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Prometheus Laboratories, Inc. develops and commercializes novel pharmaceutical and diagnostic products. Its enables physicians to provide individualized patient care. It applies the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and applies it to oncology. The firms markets and promotes pharmaceutical products and complementary proprietary diagnostic testing services. The company was founded by Jonathan Braun, Stephan R. Targan, Michael J. Walsh, and Scott L. Glenn in 1995 and is headquartered in San Diego, CA. | Direttore/Membro del Consiglio | 01/10/2020 |
| ABBVIE INC. | Corporate Officer/Principal | 01/03/2018 |
| ABBOTT LABORATORIES | Corporate Officer/Principal | 01/03/2010 |
Formazione di Mark Stenhouse
| College of Charleston | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 4 |
|---|---|
| EXACT SCIENCES CORPORATION | Health Technology |
| PHATHOM PHARMACEUTICALS, INC. | Health Technology |
| ABBOTT LABORATORIES | Health Technology |
| ABBVIE INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Prometheus Laboratories, Inc.
Prometheus Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Prometheus Laboratories, Inc. develops and commercializes novel pharmaceutical and diagnostic products. Its enables physicians to provide individualized patient care. It applies the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and applies it to oncology. The firms markets and promotes pharmaceutical products and complementary proprietary diagnostic testing services. The company was founded by Jonathan Braun, Stephan R. Targan, Michael J. Walsh, and Scott L. Glenn in 1995 and is headquartered in San Diego, CA. | Health Technology |
Prometheus Biosciences, Inc.
 Prometheus Biosciences, Inc. BiotechnologyHealth Technology Prometheus Biosciences, Inc. engages in operation of a biopharmaceutical company. It focuses on the discovery, development, and commercialization of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases. The company was founded by Scott Glenn and Stephan Targan on October 26, 2016 and is headquartered in San Diego, CA . | Health Technology |
- Borsa valori
- Insiders
- Mark Stenhouse
